EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy

Iqra Khurram iD, Mahmood S Choudhery iD, Muhammad Usman Ghani iD, Taqdees Arif iD, Aiza Naeem iD, Ruhma Mahmood iD, Ahmad Niaz iD, Muhammad Umer Khan iD

Cell Biology International · 2025

DOI: 10.1002/cbin.70082 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Biology International, 2025. Verfasst von Iqra Khurram und 7 weiteren Autor:innen. Beteiligte Einrichtung: Precision Genomics Research Lab, Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan. Hauptthemen laut MEDLINE: Cystic Fibrosis, Gene Editing, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is an inherited, autosomal recessive disorder that is caused by mutations in the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). CFTR maintains the balance between water and salts by transporting chloride ions along various epithelial surfaces. CFTR impairment affects the function of several organs, including the lungs. Newborn screening, prenatal diagnosis, and pharmacological interventions have altered the prevalence and incidence of cystic fibrosis. Although CFTR modulators are a promising treatment option, their ability to target and correct only one mutation at a time restricts their therapeutic potential. The development of genome editing technologies such as Clustered Regularly Interspaced Short Palindromic Repeats‐Cas(CRISPR‐Cas9) has the potential to correct genetic mutations, including those associated with CF, thereby offering a permanent treatment by fixing the root cause of CF. This article summarizes cystic fibrosis development, prognosis, and diagnosis, as well as possibilities for correcting various types of CFTR gene mutations. The review focuses on the potential of gene editing technologies to repair CFTR mutations and their applications in the advancement of CF treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisGene EditingCRISPR-Cas SystemsGenetic TherapyHumansCystic Fibrosis Transmembrane Conductance RegulatorMutationAnimals

Stichwörter der Autor:innen

CFTR modulatorscystic fibrosisgene editingtherapeutic potential

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • Precision Genomics Research Lab, Centre for Applied Molecular Biology, University of the Punjab, Lahore, Punjab, Pakistan.
  • Department of Human Genetics & Molecular Biology, University of Health Sciences, Lahore, Punjab, Pakistan.
  • Allama Iqbal Medical College/Jinnah Hospital, Lahore, Punjab, Pakistan.
  • Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Punjab, Pakistan.

ORCID-Profile: Iqra Khurram, Mahmood S Choudhery, Muhammad Usman Ghani, Taqdees Arif, Aiza Naeem, Ruhma Mahmood, Ahmad Niaz, Muhammad Umer Khan

Zitieren

APA

Khurram, I., Choudhery, M. S., Ghani, M. U., Arif, T., Naeem, A., Mahmood, R., Niaz, A., & Khan, M. U. (2025). Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy. Cell Biology International. https://doi.org/10.1002/cbin.70082

Vancouver

Khurram I, Choudhery MS, Ghani MU, Arif T, Naeem A, Mahmood R, et al. Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy. Cell Biology International. 2025. doi:10.1002/cbin.70082

BibTeX
@article{Khurram2025,
  author = {Khurram, Iqra and Choudhery, Mahmood S and Ghani, Muhammad Usman and Arif, Taqdees and Naeem, Aiza and Mahmood, Ruhma and Niaz, Ahmad and Khan, Muhammad Umer},
  title = {Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy},
  journal = {Cell Biology International},
  year = {2025},
  doi = {10.1002/cbin.70082}
}
Kostenlos starten →